DICK’S Prices $1.0B Senior Notes Due 2036 and 2056
DICK’S Sporting Goods closes $1.0B senior notes offering across 10-year and 30-year tranches, securing $988M net proceeds for corporate flexibility.
IPO & Public Offerings
Follow initial public offerings and other public share offerings. Learn about pricing, share sales, dilution and listing mechanics, and distinguish announced plans from completed transactions. Find your way around ECMSource.
ADARx Prices Upsized $446M Nasdaq IPO at $17 on siRNA Pipeline
ADARx Pharmaceuticals upsized its Nasdaq IPO to 26.25M shares at $17.00, raising $446.3M alongside an $89M AbbVie private placement.
Runway Growth Prices $45M Notes to Refinance 9% Senior Debt
Runway Growth Finance priced $45M of 7.75% Notes due 2031 to redeem its 9% 2027 notes and repay bank debt, extending duration at lower coupon cost.
Sysco Closes C$1.5B Notes in Multi-Tranche Jetro Financing
Sysco closed C$1.5B in Canadian senior notes and executed agreements for $14.65B in USD debt and €1.0B in EUR debt to fund its Jetro Restaurant Depot deal.
McGraw Hill Launches $500M Notes in $1.33B Debt Refinancing
McGraw Hill announced a $500 million senior secured notes offering and an $830 million Term Loan B to refinance existing credit facilities and 2028 notes.
TTM Technologies Closes $500M Senior Notes for Epiq Deal
TTM Technologies completed a $500M offering of 6.750% senior notes due 2034 to fund its $1.1B cash acquisition of Epiq Solutions and corporate needs.
Viking Therapeutics Prices Upsized $500M Dual Capital Raise
Viking Therapeutics priced an upsized $500M capital raise, pairing $275M in common stock at $35 and $225M in 2% convertible senior notes due 2032.
IQVIA Closes $2B Senior Notes Sale to Refinance Debt
IQVIA completed a $2.0B sale of 6.375% senior notes due 2034 to redeem its 5.000% 2026 notes and pay down revolving debt, pushing maturities out eight years.
Halozyme Inks $1.5B Convertible Debt Deal and Capped Calls
Halozyme closed a $1.5B convertible debt offering with capped calls, refinancing 2027 and 2028 notes while securing over $630M in fresh liquidity.
Iambic Therapeutics Files Form S-1 for Nasdaq IPO Under IAM
Iambic Therapeutics filed a Form S-1 with the SEC to list on Nasdaq under IAM, backed by Nvidia and Coatue, with $207.9M in cash and clinical HER2 data.